Company Overview and News

 
Boeing, Airbus expect Indian airlines to order up to 1740 jets by 2034

2016-03-17 business-standard
Boeing Co and Airbus Group SE said on Thursday they expect Indian airlines to order up to 1740 jets over the next 20 years, as aircraft manufacturers eye one of the world's fastest-growing aviation markets to offset any weaker sales elsewhere.

 
Boeing, Airbus eye Indian growth as fears of global slowdown mount

2016-03-17 in.reuters
HYDERABAD, India Boeing Co and Airbus Group SE said on Thursday they expect Indian airlines to order up to 1740 jets over the next 20 years, as aircraft manufacturers eye one of the world's fastest-growing aviation markets to offset any weaker sales elsewhere.

 
Boeing, Airbus eye Indian growth as fears of global slowdown mount

2016-03-17 reuters
HYDERABAD, India Boeing Co (BA.N) and Airbus Group SE (AIR.PA) said on Thursday they expect Indian airlines to order up to 1740 jets over the next 20 years, as aircraft manufacturers eye one of the world's fastest-growing aviation markets to offset any weaker sales elsewhere.

 
Qatar Airways still keen on buying stake in Indigo

2016-03-16 livemint
Qatar Airways group chief executive of Akbar Al Baker says his airline could not invest in IndiGo’s initial public offer owing to government regulations

 
For SpiceJet, an equity tangle looms

2016-03-16 business-standard
The SpiceJet turnaround story could hit air pockets if the equity dilution after the warrant conversion by the erstwhile promoters (the Marans) takes place. Not only will the Marans get a hefty 23.9 per cent of the expanded equity base, it will also mean that two former and current promoters having a substantial stake could be detrimental to the company’s fortunes. Mayur Milak of Anand Rathi Research says the warrant conversion and the outcomes would complicate the situation.

 
SpiceJet: The equity tangle

2016-03-16 business-standard
The SpiceJet turnaround story could hit a couple of air pockets if the potential equity dilution post the warrant conversion by erstwhile promoters (Marans) takes place. Not only will the Marans get a hefty 23.9% of the expanded equity base but it will also mean two former and current promoters having a substantial stake in the entity which could be detrimental to the fortunes of the company.

 
Air India’s Nagpur MRO seeks defence business

2016-03-16 livemint
Air India is also approaching domestic airlines such as Jet Airways, IndiGo, GoAir and SpiceJet to service their aircraft at the Nagpur MRO

 
SpiceJet to pass board resolution within 3 days for issuance of warrants: HC

2016-03-15 livemint
Court also seeks the release of Rs.100 crore by Kalanithi Maran and KAL Airways to SpiceJet as per the sale-purchase agreement

 
The end of Kingfisher Airlines

2016-03-15 thestar.com.my
NEW DELHI: In an airfield in southern India, seven planes of the failed Kingfisher Airlines Ltd rust away – relics of a former billionaire’s ambition and emblems of the complex regulations that hamper Indian aviation.

 
Rusty jets on tarmac show besieged Vijay Mallya’s fallen empire

2016-03-14 livemint
Seven decaying planes of the failed Kingfisher Airlines are relics of Vijay Mallya’s ambition and emblems of the complex regulations that hamper Indian aviation

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...